The quality of reporting of phase II and III trials for new antipsychotics: a systematic review

M X Patel; S Collins; J Hellier; G Bhatia; R M Murray

doi:10.1017/S0033291714001214

The quality of reporting of phase II and III trials for new antipsychotics: a systematic review

M X Patel, S Collins, J Hellier, G Bhatia, R M Murray

King's College London

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The findings of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) called previous trials of antipsychotics into question, including pre-licensing trials. Concerns regarding methodological robustness and quality of reporting increased. This systematic review aimed to examine the quality of reporting of phase II and III trials for new antipsychotics in the aftermath of the CATIE and CUtLASS studies.

Original language	English
Pages (from-to)	467-479
Number of pages	13
Journal	Psychological Medicine
Volume	45
Issue number	3
Early online date	2 Jun 2014
DOIs	https://doi.org/10.1017/S0033291714001214
Publication status	Published - 2 Jan 2015

Access to Document

10.1017/S0033291714001214

Cite this

@article{db0304db95064376b5df707224861c7f,

title = "The quality of reporting of phase II and III trials for new antipsychotics: a systematic review",

abstract = "The findings of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) called previous trials of antipsychotics into question, including pre-licensing trials. Concerns regarding methodological robustness and quality of reporting increased. This systematic review aimed to examine the quality of reporting of phase II and III trials for new antipsychotics in the aftermath of the CATIE and CUtLASS studies.",

author = "Patel, {M X} and S Collins and J Hellier and G Bhatia and Murray, {R M}",

year = "2015",

month = jan,

day = "2",

doi = "10.1017/S0033291714001214",

language = "English",

volume = "45",

pages = "467--479",

journal = "Psychological Medicine",

issn = "0033-2917",

publisher = "Cambridge University Press",

number = "3",

}

TY - JOUR

T1 - The quality of reporting of phase II and III trials for new antipsychotics

T2 - a systematic review

AU - Patel, M X

AU - Collins, S

AU - Hellier, J

AU - Bhatia, G

AU - Murray, R M

PY - 2015/1/2

Y1 - 2015/1/2

N2 - The findings of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) called previous trials of antipsychotics into question, including pre-licensing trials. Concerns regarding methodological robustness and quality of reporting increased. This systematic review aimed to examine the quality of reporting of phase II and III trials for new antipsychotics in the aftermath of the CATIE and CUtLASS studies.

AB - The findings of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) called previous trials of antipsychotics into question, including pre-licensing trials. Concerns regarding methodological robustness and quality of reporting increased. This systematic review aimed to examine the quality of reporting of phase II and III trials for new antipsychotics in the aftermath of the CATIE and CUtLASS studies.

U2 - 10.1017/S0033291714001214

DO - 10.1017/S0033291714001214

M3 - Article

C2 - 25065545

SN - 0033-2917

VL - 45

SP - 467

EP - 479

JO - Psychological Medicine

JF - Psychological Medicine

IS - 3

ER -

The quality of reporting of phase II and III trials for new antipsychotics: a systematic review

Abstract

Access to Document

Fingerprint

Cite this